223 related articles for article (PubMed ID: 16556892)
21. Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.
Donskov F; Middleton M; Fode K; Meldgaard P; Mansoor W; Lawrance J; Thatcher N; Nellemann H; von der Maase H
Br J Cancer; 2005 Oct; 93(7):757-62. PubMed ID: 16136045
[TBL] [Abstract][Full Text] [Related]
22. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Baer MR; George SL; Caligiuri MA; Sanford BL; Bothun SM; Mrózek K; Kolitz JE; Powell BL; Moore JO; Stone RM; Anastasi J; Bloomfield CD; Larson RA
J Clin Oncol; 2008 Oct; 26(30):4934-9. PubMed ID: 18591543
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cortes JE; Kantarjian HM; O'Brien S; Giles F; Keating MJ; Freireich EJ; Estey EH
Cancer; 1999 Apr; 85(7):1506-13. PubMed ID: 10193940
[TBL] [Abstract][Full Text] [Related]
24. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
Martner A; Rydström A; Riise RE; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB
Oncoimmunology; 2016; 5(1):e1041701. PubMed ID: 26942055
[TBL] [Abstract][Full Text] [Related]
25. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
26. Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.
Montesinos P; Buccisano F; Cluzeau T; Vennström L; Heuser M
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791903
[TBL] [Abstract][Full Text] [Related]
27. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Middleton M; Hauschild A; Thomson D; Anderson R; Burdette-Radoux S; Gehlsen K; Hellstrand K; Naredi P
Ann Oncol; 2007 Oct; 18(10):1691-7. PubMed ID: 17709802
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.
Bernson E; Hallner A; Sander FE; Nicklasson M; Nilsson MS; Christenson K; Aydin E; Liljeqvist JÅ; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Cancer Immunol Res; 2018 Sep; 6(9):1110-1119. PubMed ID: 29980537
[TBL] [Abstract][Full Text] [Related]
29. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
Klingemann HG; Eaves CJ; Barnett MJ; Eaves AC; Hogge DE; Nantel SH; Reece E; Shepherd JD; Sutherland HJ; Phillips GL
Bone Marrow Transplant; 1994 Sep; 14(3):389-96. PubMed ID: 7994260
[TBL] [Abstract][Full Text] [Related]
30. Postconsolidation immunotherapy in leukaemia remission.
Nelson R
Lancet Oncol; 2006 May; 7(5):367. PubMed ID: 16696159
[No Abstract] [Full Text] [Related]
31. Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.
Aurelius J; Martner A; Brune M; Palmqvist L; Hansson M; Hellstrand K; Thoren FB
Haematologica; 2012 Dec; 97(12):1904-8. PubMed ID: 22689678
[TBL] [Abstract][Full Text] [Related]
32. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients.
Mehta J; Powles R; Kulkarni S; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(2):129-35. PubMed ID: 9244416
[TBL] [Abstract][Full Text] [Related]
33. Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.
Brune M; Romero AI; Hellstrand K
Inflamm Res; 2009 Apr; 58 Suppl 1():4-8. PubMed ID: 19271134
[No Abstract] [Full Text] [Related]
34. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
35. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
36. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
Perz JB; Ho AD
Future Oncol; 2008 Apr; 4(2):169-77. PubMed ID: 18407731
[TBL] [Abstract][Full Text] [Related]
37. Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.
Aurelius J; Möllgård L; Kiffin R; Ewald Sander F; Nilsson S; Thorén FB; Hellstrand K; Martner A
Leuk Lymphoma; 2019 Nov; 60(11):2771-2778. PubMed ID: 30991860
[TBL] [Abstract][Full Text] [Related]
38. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
Buyse M; Squifflet P; Lange BJ; Alonzo TA; Larson RA; Kolitz JE; George SL; Bloomfield CD; Castaigne S; Chevret S; Blaise D; Maraninchi D; Lucchesi KJ; Burzykowski T
Blood; 2011 Jun; 117(26):7007-13. PubMed ID: 21518931
[TBL] [Abstract][Full Text] [Related]
39. Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience.
Dusenbery KE; Steinbuch M; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Litz C; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):335-43. PubMed ID: 8892457
[TBL] [Abstract][Full Text] [Related]
40. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
